Follow-up study of a randomised trial in 64 adults with three prior inactivated COVID-19 vaccine doses: an mRNA booster (CS-2034) gave stronger, more consistent neutralising antibodies than an inactivated booster, with faster decline in those aged 60+.
RCTn = 64
Wu et al. The immune response of the mRNA vaccine CS-2034 as a heterologous booster before and after breakthrough infection: A follow-up study